JP2002513541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002513541A5 JP2002513541A5 JP2000523554A JP2000523554A JP2002513541A5 JP 2002513541 A5 JP2002513541 A5 JP 2002513541A5 JP 2000523554 A JP2000523554 A JP 2000523554A JP 2000523554 A JP2000523554 A JP 2000523554A JP 2002513541 A5 JP2002513541 A5 JP 2002513541A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- cell
- nkg2
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 32
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 27
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 27
- 238000000034 method Methods 0.000 description 23
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 17
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 15
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 13
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 2
- 108091008877 NK cell receptors Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9725764.6A GB9725764D0 (en) | 1997-12-04 | 1997-12-04 | HLA-E binding |
| GB9725764.6 | 1997-12-04 | ||
| PCT/GB1998/003686 WO1999028748A2 (en) | 1997-12-04 | 1998-12-04 | Hla-e binding |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008314107A Division JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002513541A JP2002513541A (ja) | 2002-05-14 |
| JP2002513541A5 true JP2002513541A5 (enExample) | 2006-01-19 |
| JP4336451B2 JP4336451B2 (ja) | 2009-09-30 |
Family
ID=10823165
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000523554A Expired - Lifetime JP4336451B2 (ja) | 1997-12-04 | 1998-12-04 | Ｈｌａ−ｅ結合 |
| JP2008314107A Expired - Lifetime JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
| JP2009191564A Expired - Lifetime JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
| JP2013006244A Abandoned JP2013081478A (ja) | 1997-12-04 | 2013-01-17 | Ｈｌａ−ｅ結合 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008314107A Expired - Lifetime JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
| JP2009191564A Expired - Lifetime JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
| JP2013006244A Abandoned JP2013081478A (ja) | 1997-12-04 | 2013-01-17 | Ｈｌａ−ｅ結合 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7410767B1 (enExample) |
| EP (2) | EP1036327B1 (enExample) |
| JP (4) | JP4336451B2 (enExample) |
| AT (1) | ATE438096T1 (enExample) |
| DE (1) | DE69841020D1 (enExample) |
| GB (1) | GB9725764D0 (enExample) |
| WO (1) | WO1999028748A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| EP1423140A2 (en) * | 2001-07-31 | 2004-06-02 | Karl Petter Söderström | Compositions and methods for modulation of immune responses |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| EP1664110B1 (en) * | 2003-08-26 | 2008-08-20 | Danmarks Tekniske Universitet | A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process |
| EP1766393A4 (en) * | 2004-05-07 | 2008-06-18 | Beckman Coulter Inc | MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS |
| EP1781313A4 (en) | 2004-06-17 | 2009-08-26 | Beckman Coulter Inc | MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE |
| EP1831258B2 (en) | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| ATE555383T1 (de) * | 2006-06-22 | 2012-05-15 | Novo Nordisk As | Lösliche heterodimere rezeptoren und ihre verwendung |
| ES2656359T3 (es) | 2006-06-30 | 2018-02-26 | Novo Nordisk A/S | Anticuerpos anti-NKG2A y usos de los mismos |
| CN101952317B (zh) | 2008-01-24 | 2015-07-22 | 诺沃-诺迪斯克有限公司 | 人化抗-人nkg2a单克隆抗体 |
| CA2838220C (en) | 2011-06-17 | 2020-07-21 | Novo Nordisk A/S | Use of nkg2a antibodies for treatment of bone loss |
| ES2871349T3 (es) | 2012-09-04 | 2021-10-28 | Inven2 As | Expansión selectiva y controlada de células NK educadas |
| AU2014248605B2 (en) * | 2013-03-12 | 2020-05-28 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of HLA |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| US20170081411A1 (en) * | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015148960A1 (en) * | 2014-03-28 | 2015-10-01 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof |
| KR102211120B1 (ko) | 2014-05-15 | 2021-02-03 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| EP3193931B1 (en) | 2014-09-16 | 2020-08-05 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
| KR102598068B1 (ko) | 2014-10-23 | 2023-11-06 | 이나뜨 파르마 에스.에이. | 항-ｎｋｇ2ａ 제제를 이용하는 암 치료 |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| CN110809580A (zh) * | 2017-01-24 | 2020-02-18 | 安贝科思生物制剂公司 | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CN111801348A (zh) * | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| CN112351795A (zh) * | 2018-02-23 | 2021-02-09 | 安贝科思生物制剂公司 | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |
| US11464840B2 (en) | 2018-02-26 | 2022-10-11 | Swey-Shen Chen | Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers |
| EA202092147A1 (ru) | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| BR112021009111A2 (pt) | 2018-11-16 | 2021-08-24 | Bristol-Myers Squibb Company | Anticorpos anti-nkg2a e usos dos mesmos |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| SG11202105480WA (en) * | 2018-12-02 | 2021-06-29 | Fate Therapeutics Inc | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| GB201909509D0 (en) * | 2019-07-02 | 2019-08-14 | Immunocore Ltd | Peptide-MHC complexes |
| CA3197662A1 (en) | 2020-09-30 | 2022-04-07 | Dren Bio, Inc. | Anti-cd94 antibodies and methods of use thereof |
| EP4388012A4 (en) * | 2021-08-20 | 2025-09-17 | Univ Duke | ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES |
| WO2024036303A2 (en) * | 2022-08-11 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Universal t cells and compositions and methods of use thereof |
| EP4688859A1 (en) * | 2023-03-24 | 2026-02-11 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| WO2026016730A1 (zh) * | 2024-07-17 | 2026-01-22 | 广州瑞风生物科技股份有限公司 | 一种突变hla-e重链、hla-e三聚体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03112485A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112487A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞 |
| JPH03112486A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
-
1997
- 1997-12-04 GB GBGB9725764.6A patent/GB9725764D0/en not_active Ceased
-
1998
- 1998-12-04 JP JP2000523554A patent/JP4336451B2/ja not_active Expired - Lifetime
- 1998-12-04 US US09/555,555 patent/US7410767B1/en not_active Expired - Fee Related
- 1998-12-04 EP EP98959027A patent/EP1036327B1/en not_active Expired - Lifetime
- 1998-12-04 WO PCT/GB1998/003686 patent/WO1999028748A2/en not_active Ceased
- 1998-12-04 DE DE69841020T patent/DE69841020D1/de not_active Expired - Lifetime
- 1998-12-04 EP EP09165917A patent/EP2144065A1/en not_active Withdrawn
- 1998-12-04 AT AT98959027T patent/ATE438096T1/de not_active IP Right Cessation
-
2008
- 2008-04-25 US US12/109,990 patent/US20080274475A1/en not_active Abandoned
- 2008-12-10 JP JP2008314107A patent/JP4437160B2/ja not_active Expired - Lifetime
-
2009
- 2009-08-21 JP JP2009191564A patent/JP5268828B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-17 JP JP2013006244A patent/JP2013081478A/ja not_active Abandoned
-
2015
- 2015-04-10 US US14/683,835 patent/US20150361180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009106299A5 (enExample) | ||
| Orlando et al. | Analysis of chromatin structure byin VivoFormaldehyde cross-linking | |
| Tagle et al. | Magnetic bead capture of expressed sequences encoded within large genomic segments | |
| JP2854904B2 (ja) | 遺伝子の検査方法 | |
| DE3586660T2 (de) | Hybridisierungstest fuer nukleinsaeure. | |
| US20050069931A1 (en) | Non-invasive diagnostic test utilizing histone modification markers | |
| WO2002055985A3 (en) | Methods and reagents for identifying rare fetal cells in the material circulation | |
| JPH04228076A (ja) | アビジン−ビオチン開裂による一本鎖ビオチニル化核酸の調製および単離 | |
| WO2011096926A1 (en) | Methods for preparing sequencing libraries | |
| CA2425545A1 (en) | Methods of identification and isolation of polynucleotides containing nucleic acid differences | |
| DE60045796D1 (de) | Gesamt-chromosom analyse von protein-dns wechselwirkungen | |
| EP3269813A1 (en) | Method for separating nucleic acids from fepe tissue | |
| JPH0427840B2 (enExample) | ||
| Slobodyanyuk et al. | Mapping mammalian 3D genomes by micro-C | |
| US20180355437A1 (en) | Plasma/serum target enrichment | |
| WO2024138050A1 (en) | Single-nucleus high-resolution multi-modal spatial genomics | |
| JP2006517181A (ja) | Ｂｂｂ−特異的タンパク質およびその断片を同定する方法 | |
| US8105787B2 (en) | Applications of nucleic acid fragments | |
| Enkhmandakh et al. | Generation of a mouse model for a conditional inactivation of Gtf2i allele | |
| JP2004531227A5 (enExample) | ||
| Brinkman et al. | Allele-specific quantification of TNFA transcripts in rheumatoid arthritis | |
| CA3087670A1 (en) | Semi-automated research instrument system | |
| JP2003509066A5 (enExample) | ||
| JP4735926B2 (ja) | 核酸の高効率回収方法 | |
| CN103097550B (zh) | 用于分离结合至任何类型的目的核酸序列的蛋白质的方法 |